Role of CTLA4 in the Proliferation and Survival of Chronic Lymphocytic Leukemia

PLoS ONE

Volumn 8, Issue 8, 2013, Pages

  Mittal, Amit K ^a   Chaturvedi, Nagendra K ^a   Rohlfsen, Rae A ^a   Gupta, Payal ^a   Joshi, Avadhut D ^a   Hegde, Ganapati V ^a   Bociek, R Gregory ^b   Joshi, Shantaram S ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD38 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; KI 67 ANTIGEN; MYC PROTEIN; PROTEIN BCL 2; PROTEIN C FOS; PROTEIN NFATC2; STAT1 PROTEIN; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ANTIGEN FUNCTION; APOPTOSIS; ARTICLE; B LYMPHOCYTE; CANCER GROWTH; CANCER PROGNOSIS; CANCER SURVIVAL; CARCINOGENESIS; CELL CULTURE; CELL SURVIVAL; CHROMOSOME ABERRATION; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; INTRACELLULAR SIGNALING; LYMPHOCYTE PROLIFERATION; MAJOR CLINICAL STUDY; MOLECULAR PATHOLOGY; OUTCOME ASSESSMENT; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN MICROARRAY; PROTEIN PHOSPHORYLATION; TUMOR MICROENVIRONMENT; WESTERN BLOTTING;

ANTIGENS, CD38; APOPTOSIS; B-LYMPHOCYTES; CELL PROLIFERATION; CELL SURVIVAL; CTLA-4 ANTIGEN; DOWN-REGULATION; GENE SILENCING; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; PROGNOSIS; RNA, SMALL INTERFERING; TUMOR MICROENVIRONMENT;

EID: 84880985397     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0070352     Document Type: Article

References (54)

1. Dighiero G, Hamblin TJ, (2008) Chronic lymphocytic leukaemia. Lancet 371: 1017-29.
2. Chiorazzi N, Rai KR, Ferrarini M, (2005) Chronic lymphocytic leukemia. N Engl J Med 352: 804-15.
3. Damle RN, Temburni S, Calissano C, Yancopoulos S, Banapour T, et al. (2007) CD38 expression labels an activated subset within chronic lymphocytic leukemia clones enriched in proliferating B cells. Blood 110: 3352-9.
4. Dickinson JD, Joshi A, Iqbal J, Sanger W, Bierman PJ, et al. (2006) Genomic abnormalities in chronic lymphocytic leukemia influence gene expression by a gene dosage effect. Int J Mol Med 17: 769-78.
5. Joshi AD, Hegde GV, Dickinson JD, Mittal AK, Lynch JC, et al. (2007) ATM, CTLA4, MNDA, and HEM1 in high versus low CD38 expressing B-cell chronic lymphocytic leukemia. Clin Cancer Res 13: 5295-304.
6. Deaglio S, Vaisitti T, Bergui L, Bonello L, Horenstein AL, et al. (2005) CD38 and CD100 lead a network of surface receptors relaying positive signals for B-CLL growth and survival. Blood 105: 3042-50.
7. Durig J, Naschar M, Schmucker U, Renzing-Kohler K, Holter T, et al. (2002) CD38 expression is an important prognostic marker in chronic lymphocytic leukaemia. Leukemia 16: 30-5.
8. Suwalska K, Pawlak E, Karabon L, Tomkiewicz A, Dobosz T, et al. (2008) Association studies of CTLA-4, CD28, and ICOS gene polymorphisms with B-cell chronic lymphocytic leukemia in the polish population. Hum Immunol 69: 193-201.
9. Harper K, Balzano C, Rouvier E, Mattei MG, Luciani MF, et al. (1991) CTLA-4 and CD28 activated lymphocyte molecules are closely related in both mouse and human as to sequence, message expression, gene structure, and chromosomal location. J Immunol 147: 1037-44.
10. Collins AV, Brodie DW, Gilbert RJ, Iaboni A, Manso-Sancho R, et al. (2002) The interaction properties of costimulatory molecules revisited. Immunity 17: 201-10.
11. Parry RV, Chemnitz JM, Frauwirth KA, Lanfranco AR, Braunstein I, et al. (2005) CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms. Mol Cell Biol 25: 9543-53.
12. Brunner MC, Chambers CA, Chan FK, Hanke J, Winoto A, et al. (1999) CTLA-4-mediated inhibition of early events of T cell proliferation. J Immunol 162: 5813-20.
13. Greenwald RJ, Oosterwegel MA, van der Woude D, Kubal A, Mandelbrot DA, et al. (2002) CTLA-4 regulates cell cycle progression during a primary immune response. Eur J Immunol 32: 366-73.
14. Motta M, Rassenti L, Shelvin BJ, Lerner S, Kipps TJ, et al. (2005) Increased expression of CD152 (CTLA-4) by normal T lymphocytes in untreated patients with B-cell chronic lymphocytic leukemia. Leukemia 19: 1788-93.
15. Kosmaczewska A, Ciszak L, Suwalska K, Wolowiec D, Frydecka I, (2005) CTLA-4 overexpression in CD19+/CD5+ cells correlates with the level of cell cycle regulators and disease progression in B-CLL patients. Leukemia 19: 301-4.
16. Sun H, Subbotin V, Chen C, Aitouche A, Valdivia LA, et al. (1997) Prevention of chronic rejection in mouse aortic allografts by combined treatment with CTLA4-ig and anti-CD40 ligand monoclonal antibody. Transplantation 64: 1838-43.
17. Hurwitz AA, Yu TF, Leach DR, Allison JP, (1998) CTLA-4 blockade synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma. Proc Natl Acad Sci U S A 95: 10067-71.
18. Oracki SA, Tsantikos E, Quilici C, Light A, Schmidt T, et al. (2010) CTLA4Ig alters the course of autoimmune disease development in lyn-/- mice. J Immunol 184: 757-63.
19. Shen Y, Iqbal J, Xiao L, Rosenwald A, Staudt LM, et al. (2004) Distinct gene expression profiles in different B-cell compartments in human peripheral lymphoid organs. BMC Immunol 5: 20.
20. Zhang L, Murray F, Rassenti LZ, Pu M, Kelly C, et al. (2011) Cyclic nucleotide phosphodiesterase 7B mRNA: an unfavorable characteristic in chronic lymphocytic leukemia. Int J Cancer 129: 1162-9.
21. Mittal AK, Hegde GV, Aoun P, Bociek RG, Dave BJ, et al. (2007) Molecular basis of aggressive disease in chronic lymphocytic leukemia patients with 11q deletion and trisomy 12 chromosomal abnormalities. Int J Mol Med 20: 461-9.
22. Aoun P, Blair HE, Smith LM, Dave BJ, Lynch J, et al. (2004) Fluorescence in situ hybridization detection of cytogenetic abnormalities in B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma. Leuk Lymphoma 45: 1595-603.
23. Hegde GV, Peterson KJ, Emanuel K, Mittal AK, Joshi AD, et al. (2008) Hedgehog-induced survival of B-cell chronic lymphocytic leukemia cells in a stromal cell microenvironment: A potential new therapeutic target. Mol Cancer Res 6: 1928-36.
24. Tivol EA, Borriello F, Schweitzer AN, Lynch WP, Bluestone JA, et al. (1995) Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 3: 541-7.
25. Waterhouse P, Penninger JM, Timms E, Wakeham A, Shahinian A, et al. (1995) Lymphoproliferative disorders with early lethality in mice deficient in ctla-4. Science 270: 985-8.
26. Scheipers P, Reiser H, (1998) Fas-independent death of activated CD4(+) T lymphocytes induced by CTLA-4 crosslinking. Proc Natl Acad Sci U S A 95: 10083-8.
27. Doyle AM, Mullen AC, Villarino AV, Hutchins AS, High FA, et al. (2001) Induction of cytotoxic T lymphocyte antigen 4 (CTLA-4) restricts clonal expansion of helper T cells. J Exp Med 194: 893-902.
28. Pandiyan P, Gartner D, Soezeri O, Radbruch A, Schulze-Osthoff K, et al. (2004) CD152 (CTLA-4) determines the unequal resistance of Th1 and Th2 cells against activation-induced cell death by a mechanism requiring PI3 kinase function. J Exp Med 199: 831-42.
29. Salvi S, Fontana V, Boccardo S, Merlo DF, Margallo E, et al. (2012) Evaluation of CTLA-4 expression and relevance as a novel prognostic factor in patients with non-small cell lung cancer. Cancer Immunol Immunother 61: 1463-72.
30. Greenfield EA, Howard E, Paradis T, Nguyen K, Benazzo F, et al. (1997) B7.2 expressed by T cells does not induce CD28-mediated costimulatory activity but retains CTLA4 binding: Implications for induction of antitumor immunity to T cell tumors. J Immunol 158: 2025-34.
31. Cross AH, Lyons JA, San M, Keeling RM, Ku G, et al. (1999) T cells are the main cell type expressing B7-1 and B7-2 in the central nervous system during acute, relapsing and chronic experimental autoimmune encephalomyelitis. Eur J Immunol 29: 3140-7.
32. Quandt D, Hoff H, Rudolph M, Fillatreau S, Brunner-Weinzierl MC, (2007) A new role of CTLA-4 on B cells in thymus-dependent immune responses in vivo. J Immunol 179: 7316-24.
33. Vogt B, Warncke M, Micheel B, Sheriff A, (2009) Lentiviral gene transfer of CTLA4 generates B cells with reduced costimulatory properties. Autoimmunity 42: 380-2.
34. Tomic J, White D, Shi Y, Mena J, Hammond C, et al. (2006) Sensitization of IL-2 signaling through TLR-7 enhances B lymphoma cell immunogenicity. J Immunol 176: 3830-9.
35. Kay NE, Bone ND, Lee YK, Jelinek DF, Leland P, et al. (2005) A recombinant IL-4-pseudomonas exotoxin inhibits protein synthesis and overcomes apoptosis resistance in human CLL B cells. Leuk Res 29: 1009-18.
36. Lee YK, Shanafelt TD, Bone ND, Strege AK, Jelinek DF, et al. (2005) VEGF receptors on chronic lymphocytic leukemia (CLL) B cells interact with STAT 1 and 3: Implication for apoptosis resistance. Leukemia 19: 513-23.
37. Martinez-Lostao L, Briones J, Forne I, Forne I, Martinez-Gallo M, et al. (2005) Role of the STAT1 pathway in apoptosis induced by fludarabine and JAK kinase inhibitors in B-cell chronic lymphocytic leukemia. Leuk Lymphoma 46: 435-42.
38. Schuh K, Avots A, Tony HP, Serfling E, Kneitz C, (1996) Nuclear NF-ATp is a hallmark of unstimulated B cells from B-CLL patients. Leuk Lymphoma 23: 583-92.
39. Muzio M, Apollonio B, Scielzo C, Frenquelli M, Vandoni I, et al. (2008) Constitutive activation of distinct BCR-signaling pathways in a subset of CLL patients: A molecular signature of anergy. Blood 112: 188-95.
40. Gibson HM, Hedgcock CJ, Aufiero BM, Wilson AJ, Hafner MS, et al. (2007) Induction of the CTLA-4 gene in human lymphocytes is dependent on NFAT binding the proximal promoter. J Immunol 179: 3831-40.
41. Seldeen KL, McDonald CB, Deegan BJ, Farooq A, (2008) Coupling of folding and DNA-binding in the bZIP domains of jun-fos heterodimeric transcription factor. Arch Biochem Biophys 473: 48-60.
42. Malnou CE, Salem T, Brockly F, Wodrich H, Piechaczyk M, et al. (2007) Heterodimerization with jun family members regulates c-fos nucleocytoplasmic traffic. J Biol Chem 282: 31046-59.
43. Carbone M, Rossi MN, Cavaldesi M, Notari A, Amati P, et al. (2008) Poly(ADP-ribosyl)ation is implicated in the G0-G1 transition of resting cells. Oncogene 27: 6083-92.
44. Abdel-Malak NA, Srikant CB, Kristof AS, Magder SA, Di Battista JA, et al. (2008) Angiopoietin-1 promotes endothelial cell proliferation and migration through AP-1-dependent autocrine production of interleukin-8. Blood 111: 4145-54.
45. Kienle D, Benner A, Krober A, Winkler D, Mertens D, et al. (2006) Distinct gene expression patterns in chronic lymphocytic leukemia defined by usage of specific VH genes. Blood 107: 2090-3.
46. Redondo-Munoz J, Jose Terol M, Garcia-Marco JA, Garcia-Pardo A, (2008) Matrix metalloproteinase-9 is up-regulated by CCL21/CCR7 interaction via extracellular signal-regulated kinase-1/2 signaling and is involved in CCL21-driven B-cell chronic lymphocytic leukemia cell invasion and migration. Blood 111: 383-6.
47. Lima MA, Ferreira MV, Barros MA, Pardini MI, Ferrasi AC, et al. (2008) Relationship between EBV infection and expression of cellular proteins c-myc, bcl-2, and bax in gastric carcinomas. Diagn Mol Pathol 17: 82-9.
48. Palacios F, Moreno P, Morande P, Abreu C, Correa A, et al. (2010) High expression of AID and active class switch recombination might account for a more aggressive disease in unmutated CLL patients: Link with an activated microenvironment in CLL disease. Blood 115: 4488-96.
49. McCarthy BA, Boyle E, Wang XP, Guzowski D, Paul S, et al. (2008) Surface expression of bcl-2 in chronic lymphocytic leukemia and other B-cell leukemias and lymphomas without a breakpoint t(14;18). Mol Med 14: 618-27.
50. Burger JA, Ghia P, Rosenwald A, Caligaris-Cappio F, (2009) The microenvironment in mature B-cell malignancies: A target for new treatment strategies. Blood 114: 3367-75.
51. Cols M, Barra CM, He B, Puga I, Xu W, et al. (2012) Stromal endothelial cells establish a bidirectional crosstalk with chronic lymphocytic leukemia cells through the TNF-related factors BAFF, APRIL, and CD40L. J Immunol 188: 6071-83.
52. Gilling CE, Mittal AK, Chaturvedi NK, Iqbal J, Aoun P, et al. (2012) Lymph node-induced immune tolerance in chronic lymphocytic leukaemia: a role for caveolin-1. Br J Haematol158: 216-31.
53. Herishanu YP, Perez-Galan D, Liu A, Biancotto S, Pittaluga B, et al. (2011) The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia. Blood 117: 563-574.
54. Patten PE, Buggins AG, Richards J, Wotherspoon A, Salisbury J, et al. (2008) CD38 expression in chronic lymphocytic leukemia is regulated by the tumor microenvironment. Blood 111: 5173-81.